Background: Prostate cancer (PCa) is one of the most commonly diagnosed neoplasms and the second leadingcause of cancer death in men in the Western world. Vitamin D (1,25dihydroxy vitamin D) is linked to manybiological processes that influence oncogenesis but data on relations between its genetic variants and cancerrisk have been inconsistent. The aim of this study was to determine associations between a vitamin D geneticpolymorphism and 25-hydroxyvitamin D [25(OH)D] levels and prostate cancer. Materials and
Methods: GenomicDNA was extracted from 124 Jordanian prostate cancer patients and 100 healthy volunteers. Ethical approvalwas granted from the ethical committee at Hashemite University and written consent was given by all patients.PCR was used to amplify the vitamin D receptor Fok1 polymorphism fragment. 25(OH)D serum levels weremeasured by competitive immunoassay.
Results: All genotypes were in Hardy-Weinberg equilibrium. Genotypefrequency for Fok1 genotypes FF, Ff and ff was 30.7%, 61.3% and 8.06%, for prostate cancer patients, whilefrequencies for the control group was 28.0%, 66.0% and 6.0%, respectively, with no significant differences.Vitamin D serum level was significantly lower in prostate cancer patients (mean 7.7 ng/ml) compared to the controlgroup (21.8 ng/ml). No significant association was noted between 25(OH)D and VDR Fok1 gene polymorphismamong Jordanians overall, but significant associations were evident among prostate cancer patients (FF, Ff andff : 25(OH)D levels of 6.2, 8.2 and 9.9) and controls (19.0, 22.5 and 26.3, respectively). An inverse associationwas noted between 25(OH)D serum level less than 10ng/ml and prostate cancer risk (OR 35.5 and 95% CI 14.3-88.0).
Conclusions: There is strong inverse association between 25(OH)D serum level less than 10ng/ml leveland prostate cancer risk.